Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Investment Securities (2018 - 2025)

Revolution Medicines (RVMD) has 7 years of Gains from Investment Securities data on record, last reported at $19.7 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 592.56% year-over-year to $19.7 million; the TTM value through Dec 2025 reached $22.5 million, up 619.5%, while the annual FY2025 figure was $22.5 million, 60.58% up from the prior year.
  • Gains from Investment Securities reached $19.7 million in Q4 2025 per RVMD's latest filing, up from $2.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $19.7 million in Q4 2025 and bottomed at -$4.3 million in Q3 2024.
  • Average Gains from Investment Securities over 5 years is $1.1 million, with a median of $70264.5 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: surged 3365.38% in 2022, then plummeted 431900.0% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $104000.0 in 2021, then soared by 3365.38% to $3.6 million in 2022, then tumbled by 124.11% to -$869000.0 in 2023, then crashed by 360.87% to -$4.0 million in 2024, then surged by 592.56% to $19.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $19.7 million in Q4 2025, $2.7 million in Q3 2025, and $765000.0 in Q2 2025.